KR20100116607A - 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체 - Google Patents

항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체 Download PDF

Info

Publication number
KR20100116607A
KR20100116607A KR1020107017777A KR20107017777A KR20100116607A KR 20100116607 A KR20100116607 A KR 20100116607A KR 1020107017777 A KR1020107017777 A KR 1020107017777A KR 20107017777 A KR20107017777 A KR 20107017777A KR 20100116607 A KR20100116607 A KR 20100116607A
Authority
KR
South Korea
Prior art keywords
pyrazolo
pyrimidin
phenyl
amine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107017777A
Other languages
English (en)
Korean (ko)
Inventor
두르가 프라사드 코나칸치
수바 라오 풀라
락쉬미 아난타네니
라마크리시나 필리
레디 무다사니 풀라
칼리 사탸 부장아 라오 아디바틀라
초우다리 난나파네니 벤카이아
Original Assignee
낫코 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 낫코 파마 리미티드 filed Critical 낫코 파마 리미티드
Publication of KR20100116607A publication Critical patent/KR20100116607A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107017777A 2008-01-11 2009-01-12 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체 Withdrawn KR20100116607A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN109/CHE/2008 2008-01-11
IN109CH2008 2008-01-11

Publications (1)

Publication Number Publication Date
KR20100116607A true KR20100116607A (ko) 2010-11-01

Family

ID=40933862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107017777A Withdrawn KR20100116607A (ko) 2008-01-11 2009-01-12 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체

Country Status (18)

Country Link
US (1) US8349847B2 (enExample)
EP (1) EP2247596A2 (enExample)
JP (1) JP2011509290A (enExample)
KR (1) KR20100116607A (enExample)
CN (1) CN101965350A (enExample)
AP (1) AP2010005347A0 (enExample)
AU (1) AU2009211004C1 (enExample)
BR (1) BRPI0906475A2 (enExample)
CA (1) CA2711777A1 (enExample)
CO (1) CO6382174A2 (enExample)
EA (1) EA201070841A1 (enExample)
GE (1) GEP20135780B (enExample)
IL (1) IL206811A0 (enExample)
MA (1) MA32009B1 (enExample)
MX (1) MX2010007523A (enExample)
NZ (1) NZ586642A (enExample)
WO (1) WO2009098715A2 (enExample)
ZA (1) ZA201004823B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN102746307B (zh) * 2012-07-09 2013-07-31 四川大学 1-n-苄基别嘌醇衍生物及其制备方法和用途
CN102746309B (zh) * 2012-07-09 2013-06-05 四川大学 1-N-乙基-4-N-2′-取代酰基肼-1H-吡唑[3,4-d]嘧啶类衍生物及其制备方法和用途
CN103965202B (zh) * 2014-05-21 2016-01-20 邹宏丽 二环稠合杂环化合物、其制备方法及用途
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CN106008527B (zh) * 2016-06-29 2018-05-15 四川大学华西医院 吡唑并[3,4-d]嘧啶衍生物
CN107698596A (zh) * 2017-11-15 2018-02-16 双鹤药业（商丘）有限责任公司 一种别嘌醇的合成方法
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
US20230121698A1 (en) * 2019-12-23 2023-04-20 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000688A (en) 1961-09-19 Process for vatting of vat dyestuffs
US3551428A (en) 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
JPS5439096A (en) 1977-08-27 1979-03-24 Lion Dentifrice Co Ltd 11phenyll1hhpyrazolo*3*44d*pyrimidinee44 carbonitrile
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5877178A (en) 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
JP4275733B2 (ja) 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジンおよびその製造法
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US6537999B2 (en) 1996-06-06 2003-03-25 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
WO1998007726A1 (en) 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
DE19709488A1 (de) 1997-03-07 1998-09-10 Basf Ag Verfahren zur N-Alkylierung von Aminen
ES2241146T3 (es) 1997-08-05 2005-10-16 Pfizer Products Inc. 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido y.
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6423871B1 (en) 1999-02-26 2002-07-23 University Of South Florida Efficient synthesis of secondary amines by selective alkylation of primary amines
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
EA007254B1 (ru) 2000-12-01 2006-08-25 Оси Фармасьютикалз, Инк. Соединения, специфические к аденозиновому а, аи арецептору, и их применение
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists

Also Published As

Publication number Publication date
WO2009098715A2 (en) 2009-08-13
MX2010007523A (es) 2010-08-18
CA2711777A1 (en) 2009-08-13
IL206811A0 (en) 2010-12-30
CO6382174A2 (es) 2012-02-15
US8349847B2 (en) 2013-01-08
JP2011509290A (ja) 2011-03-24
WO2009098715A3 (en) 2009-10-15
WO2009098715A4 (en) 2009-12-10
NZ586642A (en) 2012-04-27
MA32009B1 (fr) 2011-01-03
US20100298351A1 (en) 2010-11-25
AU2009211004C1 (en) 2013-08-01
CN101965350A (zh) 2011-02-02
GEP20135780B (en) 2013-03-11
EA201070841A1 (ru) 2011-02-28
EP2247596A2 (en) 2010-11-10
AP2010005347A0 (en) 2010-08-31
AU2009211004B2 (en) 2011-09-01
AU2009211004A2 (en) 2011-01-27
AU2009211004A1 (en) 2009-08-13
BRPI0906475A2 (pt) 2015-07-14
ZA201004823B (en) 2011-09-28

Similar Documents

Publication Publication Date Title
AU2009211004B2 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
CA2127411C (en) Tricyclic derivatives
JP4134227B2 (ja) 縮合複素環化合物
ES2174250T5 (es) Inhibidores irreversibles de tirosina quinasas.
KR101362621B1 (ko) 화합물
JP2007516180A (ja) ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
SK89596A3 (en) Tricyclic compounds, pharmaceutical compositions on their base and prevention method of blastocyst implatation
WO2008021859A1 (en) Pyrrolotriazine kinase inhibitors
JP2010523712A (ja) 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
MXPA04001191A (es) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina.
WO2008058126A2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CN101189239A (zh) 蛋白激酶抑制剂
US20060089358A1 (en) Pyrrolotriazine compounds
JP2009533472A (ja) 癌治療法
EP3801538B1 (en) Tlr7 agonists
JPH0625246A (ja) 医薬化合物
KR101767260B1 (ko) 피리미도 옥사진 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN101657431A (zh) 嘧啶-2，4-二胺衍生物及其作为jak2激酶抑制剂的用途
US20190135816A1 (en) Substituted pyrimidine compounds and methods of use and manufacture
HK40049659B (en) Tlr7 agonists
HK40049659A (en) Tlr7 agonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100810

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid